Nuvalent Revenue and Competitors
Estimated Revenue & Valuation
- Nuvalent's estimated annual revenue is currently $7.8M per year.
- Nuvalent's estimated revenue per employee is $57,836
- Nuvalent's total funding is $185M.
- Nuvalent's current valuation is $613.2M. (January 2022)
Employee Data
- Nuvalent has 134 Employees.
- Nuvalent grew their employee count by 46% last year.
Nuvalent's People
| Name | Title | Email/Phone |
|---|---|---|
1 | CEO | Reveal Email/Phone |
2 | VP, Clinical Operations | Reveal Email/Phone |
3 | VP, Biology | Reveal Email/Phone |
4 | Head Talent Acquisition | Reveal Email/Phone |
5 | VP, Corporate Strategy & Portfolio Management | Reveal Email/Phone |
6 | VP, Biostatistics and Programming | Reveal Email/Phone |
7 | VP, Clinical Development | Reveal Email/Phone |
8 | Controller | Reveal Email/Phone |
9 | VP, IT | Reveal Email/Phone |
10 | VP Clinical Development | Reveal Email/Phone |
Nuvalent Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $5.2M | 67 | -45% | $107.3M | N/A |
#2 | $0.3M | 2 | 0% | N/A | N/A |
#3 | $5.1M | 33 | 6% | N/A | N/A |
#4 | $11.9M | 77 | -37% | $312.8M | N/A |
#5 | $0.9M | 6 | 0% | N/A | N/A |
#6 | $235M | 300 | -5% | $340.9M | N/A |
#7 | $45.9M | 237 | -7% | $7.6M | N/A |
#8 | $3.9M | 50 | 35% | N/A | N/A |
#9 | $5.4M | 35 | 3% | N/A | N/A |
#10 | $1.6M | 10 | 0% | N/A | N/A |
What Is Nuvalent?
Nuvalent is creating precisely targeted therapies for patients with cancer designed to overcome the limitations of existing therapies for clinically proven kinase targets. Leveraging deep expertise in structure-based design, Nuvalent develops innovative small molecules with exquisite target selectivity to overcome resistance, minimize adverse events, and drive more durable responses. Nuvalent is advancing a robust pipeline with parallel lead programs in ROS1-positive and ALK-positive NSCLC, along with multiple discovery-stage research programs. To learn more, visit www.nuvalent.com.
keywords:N/A
$185M
Total Funding
134
Number of Employees
$7.8M
Revenue (est)
46%
Employee Growth %
$613.2M
Valuation
N/A
Accelerator
Nuvalent News
Nuvalent Presents New Data Demonstrating Expanded Preclinical Activity with ROS1-Selective Inhibitor NVL-520 and ALK-Selective Inhibitor NVL-655...
CAMBRIDGE, Mass., March 31, 2022 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical stage biopharmaceutical company creating precisely...
Nuvalent plans to initiate the ALKOVE-1 Phase 1/2 study of NVL-655 for patients with advanced ALK-positive non-small cell lung cancer (NSCLC)...
CAMBRIDGE, Mass., Sept. 8, 2021 /PRNewswire/ -- Nuvalent, Inc., (Nasdaq: NUVL), a biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today reported recent pipeline and business highlights and second quarter 2021 financial ...
Nuvalent, Inc., a Cambridge, Mass.-based biotechnology company creating precisely targeted therapies for clinically proven kinase targets in cancer, closed a $135m Series B financing. The round was led by Bain Capital Life Sciences with participation from sole founding investor, Deerfield Manag ...
Other Companies in Cambridge
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $13.7M | 134 | 8% | N/A |
#2 | $33.8M | 135 | N/A | N/A |
#3 | $13.5M | 135 | 9% | N/A |
#4 | $28.6M | 136 | -8% | N/A |
#5 | $24.5M | 136 | 5% | N/A |